Citi opens ‘positive catalyst watch’ on Mirum into data

Citi analyst David Lebowitz opened a “30-day positive catalyst watch” on shares of Mirum Pharmaceuticals saying interim analyses of volixibat’s Phase 2b VISTAS trial and VANTAGE trials in primary sclerosing cholangitis and primary biliary cholangitis are expected concurrently in June. Investor focus on volixibat has been limited, says Citi, which believes the drug could meet the prespecified bar for PSC-itch benefit, advancing VISTAS to pivotal stage, while conferring meaningful PBC-itch benefit in VANTAGE. Such positive updates will boost investor confidence on volixibat prospects, which should lead to stock upside, the analyst tells investors in a research note. The firm has a Buy rating on Mirum with a $38 price target.